DISC-0974
Anemia of Myelofibrosis (MF)
Key Facts
About Disc Medicine
Disc Medicine is a publicly traded biotech company focused on transforming the treatment landscape for hematologic diseases by targeting fundamental pathways in red blood cell biology and iron metabolism. The company has built a diversified pipeline through strategic in-licensing of clinical-stage assets from Roche, AbbVie, and Mabwell, with its lead program, bitopertin, in Phase 3 development for erythropoietic protoporphyria. With a seasoned leadership team and a clear focus on hematology, Disc Medicine aims to address significant unmet needs in both rare and common blood disorders.
View full company profileAbout Disc Medicine
Disc Medicine is a publicly traded biotech company focused on transforming the treatment landscape for hematologic diseases by targeting fundamental pathways in red blood cell biology and iron metabolism. The company has built a diversified pipeline through strategic in-licensing of clinical-stage assets from Roche, AbbVie, and Mabwell, with its lead program, bitopertin, in Phase 3 development for erythropoietic protoporphyria. With a seasoned leadership team and a clear focus on hematology, Disc Medicine aims to address significant unmet needs in both rare and common blood disorders.
View full company profileAbout Disc Medicine
Disc Medicine is a publicly traded biotech company focused on transforming the treatment landscape for hematologic diseases by targeting fundamental pathways in red blood cell biology and iron metabolism. The company has built a diversified pipeline through strategic in-licensing of clinical-stage assets from Roche, AbbVie, and Mabwell, with its lead program, bitopertin, in Phase 3 development for erythropoietic protoporphyria. With a seasoned leadership team and a clear focus on hematology, Disc Medicine aims to address significant unmet needs in both rare and common blood disorders.
View full company profile